GCG and myocardial infarction: GLP-1 RAs, originally developed as glucose-lowering agents for their incretin effects on insulin secretion, have demonstrated consistent reductions in major adverse cardiovascular events (MACE), particularly stroke and myocardial infarction, across multiple trials [46].